<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01678586</url>
  </required_header>
  <id_info>
    <org_study_id>2012P-001795</org_study_id>
    <secondary_id>5R01AT005819-04</secondary_id>
    <nct_id>NCT01678586</nct_id>
  </id_info>
  <brief_title>Effect of Acupuncture and Pain Medication on Radicular Pain Using QST</brief_title>
  <official_title>Effect of Acupuncture and Pain Medication on Radicular Pain Using QST</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this aim, we propose to conduct a double blinded, placebo-controlled, and randomized
      clinical trial to compare the clinical effectiveness of radicular pain relief by either
      acupuncture therapy or a course of pain medication (e.g., Gabapentin) using Quantitative
      Sensory Testing (QST).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in QST measures in response to acupuncture or gabapentin</measure>
    <time_frame>3 weeks</time_frame>
    <description>Changes in response to heat stimulation stated as pain, sensitivity and tolerance. Responses are measured with a quantitative sensory testing (QST) device. Measurements are taken before, during, and after acupuncture treatment and throughout the gabapentin medication regimen.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>True Acupuncture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pain subjects with radicular pain receiving 6, 30 minute acupuncture treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Acupuncture</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Pain subjects with radicular pain receiving 6, 30 minute sham acupuncture treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pain subjects with radicular pain receiving gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Gabapentin</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Pain subjects with radicular pain receiving sham gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>In true acupuncture the needles penetrate the skin.</description>
    <arm_group_label>True Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Acupuncture</intervention_name>
    <description>In sham acupuncture the needles do not penetrate the skin.</description>
    <arm_group_label>Sham Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin is a commonly prescribed drug used to treat neuropathic pain.</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham Gabapentin</intervention_name>
    <description>Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)</description>
    <arm_group_label>Sham Gabapentin</arm_group_label>
    <other_name>Benadryl, diphenhydramine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject will be between ages 18 to 75 years. Both male and female subjects will be
             recruited.

          2. Subject should have had cervical or lumbar radicular pain for at least two months.
             This requirement is to avoid the uncertainty of an unstable pain condition and to
             minimize the study variation.

          3. Subject has a pain score of 4 or above (visual analog scale, VAS: 0 - 10 from no pain
             to worst pain).

          4. Cervical or lumbar radicular pain will include, but is not limited to, such clinical
             conditions as disk herniation, spinal stenosis, and post-laminectomy syndrome.

        Exclusion Criteria:

          1. Subject has detectable sensory deficits at the site of QST. Sensory deficits refer to
             such conditions resulting from neurological diseases or medical conditions causing
             peripheral polyneuropathy and sensory changes, which include but are not limited to
             diabetic neuropathy, alcoholic neuropathy, AIDS neuropathy, severe thyroid disease,
             and severe liver or kidney disorders.

          2. Subject has scar tissue, infection, or acute injury at the site of QST.

          3. Subject is pregnant.

          4. Subject tests positive for illicit drugs.

          5. Subject has a pacemaker.

          6. Subject is currently taking gabapentin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianren Mao, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MGH Center for Translational Pain Research</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massgeneral.org/translationalpainresearch/</url>
    <description>Center for Translational Pain Research</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2012</study_first_submitted>
  <study_first_submitted_qc>September 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jianren Mao, MD, PhD</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Pain management</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

